Polaris Partners joins the parade of new biotech funds launched in 2014 with a $450M fund which exceeds $400M number they filed with the SEC last summer. Polaris joins Arch, Venrock, Versant and Sofinnova, among others, who have launched funds of similar size in 2014. http://www.fiercebiotech.com/story/polaris-adds-450m-years-bonanza-new-biotech-funds/2014-11-24?utm_medium=nl&utm_source=internal
These new funds will bring a welcome surge of new private capital to innovative biotechs. How will it be deployed and will it be enough to sustain early-stage development at a time when drug development costs are soaring? Our Wednesday plenary panel at Biotech Showcase will discuss these topics and others as they contemplate the next five years of private investment in the biopharmaceutical industry.